San Francisco, USA-based Antipodean Pharmaceuticals has initiated Phase II clinical trials to test the efficacy of its lead compound MitoQ (mitoquinone) in patients with Parkinson's disease in New Zealand and Australia.
The agent is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria where they accumulate up to 1,000-fold and significantly interrupt oxidative damage, which is implicated as a catalyst in PD, Alzheimer's disease and other neurodegenerative conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze